- £68.51bn
- £80.80bn
- £30.33bn
- 88
- 46
- 96
- 91
REG - GSK PLC - Jemperli trial meets overall survival endpoint
AnnouncementREG - GSK PLC - NMPA approves Vocabria+Rekambys in China
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - New data for Arexvy, GSK’s RSV vaccine
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Jemperli plus chemotherapy positive CHMP opinion
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Zantac (ranitidine) litigation
AnnouncementREG - Haleon PLC GSK PLC - Holding(s) in Company
AnnouncementREG - GSK PLC - GSK and Zhifei announce vaccine partnership
AnnouncementREG - GSK PLC - GSK completes sale of shares in Haleon plc
AnnouncementREG - GSK PLC - GSK announces intention to sell shares in Haleon
AnnouncementREG - Allianz Global Invs - Top 10 Holdings
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - Directorate Change
AnnouncementREG - GSK PLC - GSK RSV vaccine for older adults approved in Japan
Announcement